NASDAQ:FBLG

FibroBiologics Q4 2024 Earnings Results & Report

FibroBiologics logo
$0.84 -0.06 (-6.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.01 (-1.19%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics beat analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$1.80 versus the -$2.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

FibroBiologics EPS Results

Actual EPS
-$1.80
Consensus EPS
-$2.00
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

FibroBiologics' Q4 2026 earnings is estimated for Friday, November 20, 2026, based on past reporting schedules

FibroBiologics Q4 2024 Earnings FAQ

FibroBiologics (NASDAQ:FBLG) reported earnings of -$1.80 per share for Q4 2024, beating the consensus estimate of -$2.00. The report was announced on Monday, March 31, 2025.

FibroBiologics' next earnings date is estimated for Friday, November 20, 2026. MarketBeat tracks confirmed and estimated earnings dates for FibroBiologics on the company's earnings history page.

FibroBiologics Earnings Headlines

FibroBiologics Inc. (NASDAQ:FBLG) Stock Rated "Reduce" by Wall Street Analysts
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes.

The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

FibroBiologics is based in Houston, Texas. The company was founded by Pete O’Heeron, who serves as its chief executive officer.

View FibroBiologics Profile